Cargando…
Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with relapsed or refractory (r/r) follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1 to 3 previous therapies received Bendamustine (90 mg/m(2), day 1 + 2) and...
Autores principales: | Hess, Georg, Wagner, Karola, Keller, Ulrich, La Rosee, Paul, Atta, Johannes, Hübel, Kai, Lerchenmueller, Christian, Schoendube, Daniel, Witzens-Harig, Mathias, Ruckes, Christian, Medler, Christoph, van Oordt, Christina, Klapper, Wolfram, Theobald, Matthias, Dreyling, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306311/ https://www.ncbi.nlm.nih.gov/pubmed/32647802 http://dx.doi.org/10.1097/HS9.0000000000000398 |
Ejemplares similares
-
Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
por: Samad, Nousheen, et al.
Publicado: (2010) -
Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
por: Galimberti, S, et al.
Publicado: (2010) -
A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial
por: Witzens-Harig, Mathias, et al.
Publicado: (2013) -
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
por: Rule, S, et al.
Publicado: (2018) -
Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)